SG11202105763SA - Novel polymorphic forms of a tgf? inhibitor - Google Patents
Novel polymorphic forms of a tgf? inhibitorInfo
- Publication number
- SG11202105763SA SG11202105763SA SG11202105763SA SG11202105763SA SG11202105763SA SG 11202105763S A SG11202105763S A SG 11202105763SA SG 11202105763S A SG11202105763S A SG 11202105763SA SG 11202105763S A SG11202105763S A SG 11202105763SA SG 11202105763S A SG11202105763S A SG 11202105763SA
- Authority
- SG
- Singapore
- Prior art keywords
- tgf
- inhibitor
- polymorphic forms
- novel polymorphic
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
- C07D213/18—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782411P | 2018-12-20 | 2018-12-20 | |
| US201962930170P | 2019-11-04 | 2019-11-04 | |
| PCT/IB2019/060944 WO2020128850A1 (en) | 2018-12-20 | 2019-12-17 | Novel polymorphic forms of a tgfβ inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105763SA true SG11202105763SA (en) | 2021-07-29 |
Family
ID=69159846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105763SA SG11202105763SA (en) | 2018-12-20 | 2019-12-17 | Novel polymorphic forms of a tgf? inhibitor |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200199104A1 (zh) |
| EP (1) | EP3898591A1 (zh) |
| JP (1) | JP2022513925A (zh) |
| KR (1) | KR20210104808A (zh) |
| CN (1) | CN113272279A (zh) |
| AU (1) | AU2019404250B2 (zh) |
| BR (1) | BR112021010577A2 (zh) |
| CA (1) | CA3123829A1 (zh) |
| CL (1) | CL2021001602A1 (zh) |
| CO (1) | CO2021007875A2 (zh) |
| CR (1) | CR20210334A (zh) |
| EC (1) | ECSP21044734A (zh) |
| IL (1) | IL284226A (zh) |
| MA (1) | MA54526A (zh) |
| MX (1) | MX2021007251A (zh) |
| PE (1) | PE20211756A1 (zh) |
| SG (1) | SG11202105763SA (zh) |
| TW (1) | TWI743631B (zh) |
| UY (1) | UY38517A (zh) |
| WO (1) | WO2020128850A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022130206A1 (en) * | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
| CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
| WO2022229846A1 (en) * | 2021-04-29 | 2022-11-03 | Pfizer Inc. | Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3089971T (pt) | 2014-01-01 | 2020-09-03 | Medivation Tech Llc | Compostos e métodos de utilização |
-
2019
- 2019-12-17 WO PCT/IB2019/060944 patent/WO2020128850A1/en unknown
- 2019-12-17 JP JP2021534623A patent/JP2022513925A/ja not_active Withdrawn
- 2019-12-17 EP EP19835785.7A patent/EP3898591A1/en not_active Withdrawn
- 2019-12-17 PE PE2021000893A patent/PE20211756A1/es unknown
- 2019-12-17 MA MA054526A patent/MA54526A/fr unknown
- 2019-12-17 SG SG11202105763SA patent/SG11202105763SA/en unknown
- 2019-12-17 MX MX2021007251A patent/MX2021007251A/es unknown
- 2019-12-17 AU AU2019404250A patent/AU2019404250B2/en active Active
- 2019-12-17 KR KR1020217022254A patent/KR20210104808A/ko not_active Application Discontinuation
- 2019-12-17 US US16/716,696 patent/US20200199104A1/en active Pending
- 2019-12-17 BR BR112021010577-8A patent/BR112021010577A2/pt unknown
- 2019-12-17 CA CA3123829A patent/CA3123829A1/en active Pending
- 2019-12-17 CR CR20210334A patent/CR20210334A/es unknown
- 2019-12-17 CN CN201980086144.4A patent/CN113272279A/zh active Pending
- 2019-12-18 UY UY0001038517A patent/UY38517A/es unknown
- 2019-12-19 TW TW108146622A patent/TWI743631B/zh active
-
2021
- 2021-06-16 CO CONC2021/0007875A patent/CO2021007875A2/es unknown
- 2021-06-17 CL CL2021001602A patent/CL2021001602A1/es unknown
- 2021-06-18 EC ECSENADI202144734A patent/ECSP21044734A/es unknown
- 2021-06-20 IL IL284226A patent/IL284226A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113272279A (zh) | 2021-08-17 |
| MA54526A (fr) | 2022-03-30 |
| CA3123829A1 (en) | 2020-06-25 |
| AU2019404250B2 (en) | 2022-12-22 |
| EP3898591A1 (en) | 2021-10-27 |
| ECSP21044734A (es) | 2021-07-30 |
| AU2019404250A1 (en) | 2021-07-01 |
| BR112021010577A2 (pt) | 2021-08-24 |
| PE20211756A1 (es) | 2021-09-07 |
| CL2021001602A1 (es) | 2022-01-21 |
| KR20210104808A (ko) | 2021-08-25 |
| TWI743631B (zh) | 2021-10-21 |
| TW202039462A (zh) | 2020-11-01 |
| IL284226A (en) | 2021-08-31 |
| CR20210334A (es) | 2021-07-14 |
| JP2022513925A (ja) | 2022-02-09 |
| MX2021007251A (es) | 2021-07-15 |
| CO2021007875A2 (es) | 2021-07-19 |
| UY38517A (es) | 2020-07-31 |
| US20200199104A1 (en) | 2020-06-25 |
| WO2020128850A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201902327D0 (en) | Novel compounds | |
| EP4069212A4 (en) | HIF-2 ALPHA INHIBITORS | |
| IL283608A (en) | 15-pgdh inhibitor | |
| SG11202105763SA (en) | Novel polymorphic forms of a tgf? inhibitor | |
| GB201819126D0 (en) | Inhibitor compounds | |
| GB201912674D0 (en) | Novel compounds | |
| IL290087A (en) | inhibitory substances | |
| SG11202101622VA (en) | Novel quinoline derivative inhibitor | |
| GB201914860D0 (en) | Inhibitor compounds | |
| IL279853A (en) | Polymorphic forms of RAD 1901-2HCL | |
| GB201913548D0 (en) | Novel compounds | |
| IL285427A (en) | Crystal forms of jak2 inhibitor | |
| IL279953A (en) | Crystal forms of LTA4H inhibitor | |
| GB201905328D0 (en) | Inhibitor compounds | |
| IL284564A (en) | Polymorphic forms of a modified quinoline-type bridged piperidine compound | |
| GB201905318D0 (en) | Inhibitor compounds | |
| GB201819136D0 (en) | Inhibitor compounds | |
| IL284222A (en) | Macrocrystalline forms of the PAR4 inhibitor | |
| GB201910664D0 (en) | Novel forms of compound | |
| GB201806131D0 (en) | Inhibitor compounds | |
| GB201806130D0 (en) | Inhibitor compounds | |
| IL291368A (en) | Inhibits expression of methadherin | |
| IL288741A (en) | New spirobicyclic intermediates | |
| GB201910666D0 (en) | Novel form of compounds | |
| GB201910665D0 (en) | Novel form of compounds |